Varonis Systems, Inc. USDC – Southern District of New York january 7, 2026 CLASS PERIOD: february 4, 2025 – october 28, 2025LEAD PLAINTIFF DEADLINE: march 9, 2026 Please complete the form below to contact Kaplan Fox regarding the Varonis Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Donald R. HallDHall@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox Alerts Investors of Varonis Systems, Inc. (VRNS) to a Securities Class Action Deadline on March 9, 2026 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Varonis Systems, Inc. (VRNS) (“Varonis” or the “Company”) (NASDAQ: VRNS) on behalf of investors that purchased or otherwise acquired Varonis securities between February 4, 2025 and October 28, 2025 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you purchased Varonis securities during the Class Period and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing mail@kaplanfox.com or dhall@kaplanfox.com, or by calling (800) 290-1952. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 9, 2026 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. According to the complaint, on October 28, 2025, Varonis announced financial results for the third quarter of fiscal 2025, disclosing a significant miss to ARR and reducing its projections for the full fiscal year 2025, despite previously uplifting guidance for the previous two consecutive quarters. Further, according to the complaint, the Company attributed its results and lowered guidance to weaker than expected renewals and conversions in their federal and non-federal on-premises subscription business. On October 29, 2025, the price of Varonis shares fell $30.66 per share, over 48%, to close at $32.34 per share on October 29, 2025. The complaint alleges, that throughout the Class Period, Defendants statements were false and/or materially misleading because they created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. According to the complaint, Varonis was simply ill-equipped to continue its ARR growth trajectory without maintaining a significantly high rate of quarterly conversions. WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT:Donald R. HallKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 687-1980dhall@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1501Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Aquestive Therapeutics, Inc. See the Case Snowflake Inc. See the Case Jefferies Financial Group See the Case Ardent Health, Inc. See the Case CoreWeave, Inc. See the Case Beta Bionics, Inc. See the Case Varonis Systems, Inc. See the Case Klarna Group PLC See the Case Quantum Biopharma Ltd. See the Case Corcept Therapeutics, Inc. See the Case Coupang, Inc. See the Case James Hardie Industries plc See the Case
